Arcellx (ACLX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Arcellx (ACLX)
Arcellx Inc is a clinical-stage biotechnology company reimagining cell therapy through the development of immunotherapies for patients with cancer and other incurable diseases.
Key Insights
Critical company metrics and information
Share Price
$89.17Market Cap
$4.82 BillionTotal Outstanding Shares
54.08 Million SharesTotal Employees
130Dividend
No dividendIPO Date
February 4, 2022SIC Description
Biological Products, (no Disgnostic Substances)Homepage
https://www.arcellx.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Net Cash Flow, Continuing | $33.42 Million |
Net Cash Flow From Investing Activities | $-157.91 Million |
Net Cash Flow From Operating Activities | $20.81 Million |
Net Cash Flow From Operating Activities, Continuing | $20.81 Million |
Net Cash Flow From Investing Activities, Continuing | $-157.91 Million |
Net Cash Flow From Financing Activities, Continuing | $170.52 Million |
Net Cash Flow | $33.42 Million |
Net Cash Flow From Financing Activities | $170.52 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Average Shares | $160.38 Million |
Operating Expenses | $225.24 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Income Tax Expense/Benefit | $1.19 Million |
Income/Loss From Continuing Operations After Tax | $-40.42 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Net Income/Loss Available To Common Stockholders, Basic | $-40.42 Million |
Net Income/Loss Attributable To Parent | $-40.42 Million |
Other Operating Expenses | $82.01 Million |
Revenues | $155.82 Million |
Operating Income/Loss | $-69.42 Million |
Research and Development | $141.23 Million |
Income/Loss From Continuing Operations Before Tax | $-39.24 Million |
Diluted Earnings Per Share | $0.71 |
Costs And Expenses | $195.06 Million |
Benefits Costs and Expenses | $195.06 Million |
Diluted Average Shares | $160.38 Million |
Net Income/Loss | $-40.42 Million |
Basic Earnings Per Share | $0.71 |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Equity | $483.02 Million |
Other Current Liabilities | $131.03 Million |
Noncurrent Liabilities | $144.87 Million |
Noncurrent Assets | $177.61 Million |
Current Liabilities | $137.02 Million |
Liabilities And Equity | $764.91 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Liabilities | $281.89 Million |
Assets | $764.91 Million |
Other Non-current Assets | $130.11 Million |
Accounts Payable | $5.99 Million |
Current Assets | $587.30 Million |
Equity Attributable To Parent | $483.02 Million |
Fixed Assets | $47.50 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.